BDTX (Black Diamond Therapeutics) Total Equity: $104.30 Mil (As of Mar. 2026)


BDTX Black Diamond Therapeutics Inc BDTX
37 GF Score
Price $1.75
! 2 Warning Signs
View Full Analysis

What is Black Diamond Therapeutics Total Equity?

Black Diamond Therapeutics BDTX +2.34% 37 Total Equity is $104.30 Mil as of Mar. 2026. GuruFocus rates BDTX with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

Black Diamond Therapeutics's total equity for the quarter that ended in Mar. 2026 was $104.30 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Black Diamond Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Black Diamond Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Black Diamond Therapeutics Total Equity Chart

Black Diamond Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only 195.90 115.70 116.74 83.29 112.21

Black Diamond Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 141.52 132.61 126.15 112.21 104.30
BDTX
37GF Score
Black Diamond Therapeutics Inc BDTX
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Black Diamond Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Black Diamond Therapeutics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=143.01-30.799
=112.21

Black Diamond Therapeutics's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=132.922-28.622
=104.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $104.30 Mil mean?
Black Diamond Therapeutics (BDTX) has a Total Equity of $104.30 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Black Diamond Therapeutics and its competitors.
Is Black Diamond Therapeutics' Total Equity too high?
Black Diamond Therapeutics' current Total Equity is $104.30 Mil. Overall, Black Diamond Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Black Diamond Therapeutics' Total Equity compare to CGTX and PMN?
Black Diamond Therapeutics' Total Equity of $104.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Black Diamond Therapeutics and its competitors. Black Diamond Therapeutics's current Total Equity is $104.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Black Diamond Therapeutics stock overvalued right now?
Black Diamond Therapeutics (BDTX) has a current Total Equity of $104.30 Mil. The current Total Equity is $104.30 Mil. Black Diamond Therapeutics' overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Black Diamond Therapeutics (BDTX), the current Total Equity is $104.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Black Diamond Therapeutics Business Description

Address 245 First Street, 18th Floor, Cambridge, MA, USA, 02142
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
37GF Score

Get the complete analysis for BDTX

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.75
Price